Fate Therapeutics Inc

Fate Therapeutics is a clinical-stage biopharmaceutical company. The company's immuno-oncology product candidates include: FATE-NK100, which is a natural killer (NK) cell cancer immunotherapy comprised of adaptive memory NK cells; and FT500, which is an off-the-shelf NK cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf immunotherapy for the treatment of cancer. The company's immuno-regulation product candidates include: ProTmune?, which is an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft; and FT301, which is an off-the-shelf, immuno-regulatory cell product candidate.
  • TickerFATE
  • ISINUS31189P1021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Aug 10 2020 6:58AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

2Q20 Financials; Fate's Many Threads to Come Together in 2021

Wedbush Research

Wedbush Morning Call - Aug 10 2020 6:58AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

2Q20 Financials; Fate's Many Threads to Come Together in 2021

Wedbush Research

Wedbush Morning Call - Aug 03 2020 6:53AM

ResearchPool Subscriptions

Get the most out of your insights

Get in touch